Omicron | Jotup

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Monday, February 5, 2024

Pfizer–BioNTech COVID-19 vaccine, Pfizer, COVID-19, Omicron, BNTX, Biotechnology, BioNTech, Food, Risk, The Company, Complaint, Infection, Cancer, Court, Person, Pharmaceutical industry

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

Key Points:

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. (“Pfizer”).
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for BioNTech SE Investors in Securities Fraud Class Action Lawsuit

Retrieved on:

Sunday, February 4, 2024

RADNOR, Pa. , Feb. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points:

RADNOR, Pa. , Feb. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on:

Saturday, February 3, 2024

NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points:

NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on:

Friday, February 2, 2024

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points:

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Monday, January 29, 2024

Person, Biotechnology, Pfizer, Omicron, Cancer, Complaint, Risk, BioNTech, Infection, BNTX, Court, Food, COVID-19, The Company, Pfizer–BioNTech COVID-19 vaccine, Pharmaceutical industry

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

Key Points:

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. (“Pfizer”).
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BNTX CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against BioNTech SE (BNTX)

Retrieved on:

Saturday, January 27, 2024

RADNOR, Pa., Jan. 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points:

RADNOR, Pa., Jan. 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on:

Friday, January 26, 2024

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points:

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIONTECH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on:

Wednesday, January 24, 2024

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points:

If you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Monday, January 22, 2024

Person, Biotechnology, Pfizer, Omicron, Cancer, Complaint, Risk, BioNTech, Infection, BNTX, Court, Food, COVID-19, The Company, Pfizer–BioNTech COVID-19 vaccine, Pharmaceutical industry

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.

Key Points:

BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
The Company has developed and continues to develop, among other products and product candidates, Comirnaty, a COVID-19 vaccine, in collaboration with Pfizer Inc. (“Pfizer”).
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against BioNTech SE (BNTX)

Retrieved on:

Saturday, January 20, 2024

RADNOR, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points:

RADNOR, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.